Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

1.

Lipid Metabolism and Lipodystrophy in HIV-1-Infected Patients: The Role Played by Nonnucleoside Reverse Transcriptase Inhibitors.

Sension M, Deckx H.

AIDS Rev. 2014 Dec 4;17(1). [Epub ahead of print]

PMID:
25472015
[PubMed - as supplied by publisher]
2.

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years.

Gazzard B, Girard PM, Di Perri G, Gallant J, Towner W, Rogatto F, Demorin J, McColl D, Liu H, Rhee M, Szwarcberg J, Piontkowsky D.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19767. doi: 10.7448/IAS.17.4.19767. eCollection 2014.

PMID:
25397511
[PubMed - in process]
Free PMC Article
3.

Viral escape in the CNS with multidrug-resistant HIV-1.

Béguelin C, Vázquez M, Bertschi M, Yerly S, de Jong D, Rauch A, Cusini A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19745. doi: 10.7448/IAS.17.4.19745. eCollection 2014.

PMID:
25397490
[PubMed - in process]
Free PMC Article
4.

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, Stephens J, Nichols G.

PLoS One. 2014 Sep 4;9(9):e105653. doi: 10.1371/journal.pone.0105653. eCollection 2014.

PMID:
25188312
[PubMed - in process]
Free PMC Article
5.

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R.

J Antimicrob Chemother. 2014 Oct;69(10):2819-25. doi: 10.1093/jac/dku211. Epub 2014 Jun 19.

PMID:
24948705
[PubMed - in process]
6.

French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.

Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L'Hénaff M, Persiaux R, Rey D, Rouzioux C, Taburet AM, Morlat P; 2013 French HIV expert group.

J Int AIDS Soc. 2014 Jun 17;17:19034. doi: 10.7448/IAS.17.1.19034. eCollection 2014.

PMID:
24942364
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Impact of randomized antiretroviral therapy initiation on glucose metabolism.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, Ha B, McComsey GA.

AIDS. 2014 Jun 19;28(10):1451-61. doi: 10.1097/QAD.0000000000000266.

PMID:
24637543
[PubMed - in process]
8.

Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.

Hattab S, Guihot A, Guiguet M, Fourati S, Carcelain G, Caby F, Marcelin AG, Autran B, Costagliola D, Katlama C.

BMC Infect Dis. 2014 Mar 4;14:122. doi: 10.1186/1471-2334-14-122.

PMID:
24589015
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment.

Manzardo C, Gatell JM.

AIDS Rev. 2014 Jan-Mar;16(1):35-42. Review.

PMID:
24584107
[PubMed - indexed for MEDLINE]
10.

Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.

Imaz A, Llibre JM, Navarro J, Curto J, Clotet B, Crespo M, Ferrer E, Saumoy M, Tiraboschi JM, Murillo O, Podzamczer D.

Antivir Ther. 2014;19(6):569-77. doi: 10.3851/IMP2736. Epub 2014 Jan 23.

PMID:
24458091
[PubMed - in process]
11.

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, Melbourne K, Ha B, Jahed NC, McComsey GA.

AIDS. 2013 Aug 24;27(13):2069-79. doi: 10.1097/QAD.0b013e328361d25d.

PMID:
24384588
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.

Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A.

Ther Clin Risk Manag. 2014;10:9-15. doi: 10.2147/TCRM.S49428. Epub 2013 Dec 18.

PMID:
24379676
[PubMed]
Free PMC Article
13.
14.

Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.

[No authors listed]

Prescrire Int. 2013 Oct;22(142):233-5.

PMID:
24298581
[PubMed - indexed for MEDLINE]
15.

Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.

McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Daar ES.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):167-74. doi: 10.1097/01.qai.0000437171.00504.41.

PMID:
24121755
[PubMed - indexed for MEDLINE]
16.

Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.

Casado JL, de Los Santos I, Del Palacio M, García-Fraile L, Pérez-Elías MJ, Sanz J, Moreno S.

HIV Clin Trials. 2013 Jan-Feb;14(1):1-9. doi: 10.1410/hct1401-1.

PMID:
23372109
[PubMed - indexed for MEDLINE]
17.

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.

Andersson LM, Vesterbacka J, Blaxhult A, Flamholc L, Nilsson S, Ormaasen V, Sönnerborg A, Gisslén M.

Scand J Infect Dis. 2013 Jul;45(7):543-51. doi: 10.3109/00365548.2012.756985. Epub 2013 Jan 7.

PMID:
23294034
[PubMed - indexed for MEDLINE]
18.

Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical care.

Taniguchi T, Grubb JR, Nurutdinova D, Önen NF, Shacham E, Donovan M, Overton ET.

J Int Assoc Provid AIDS Care. 2013 Mar-Apr;12(2):138-41. doi: 10.1177/1545109712467057. Epub 2012 Dec 26.

PMID:
23269514
[PubMed - indexed for MEDLINE]
19.

Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M.

J Infect Dis. 2013 Feb 15;207(4):604-11. doi: 10.1093/infdis/jis720. Epub 2012 Nov 29.

PMID:
23204164
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, Lalama CM, Bosch RJ, Tierney C, Katzenstein D; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2012 Dec 15;206(12):1920-30. doi: 10.1093/infdis/jis613. Epub 2012 Nov 12.

PMID:
23148287
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk